<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654223</url>
  </required_header>
  <id_info>
    <org_study_id>MG56-SIT-012</org_study_id>
    <secondary_id>2014-005471-88</secondary_id>
    <nct_id>NCT02654223</nct_id>
  </id_info>
  <brief_title>Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy</brief_title>
  <acronym>MG56</acronym>
  <official_title>Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inmunotek S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inmunotek S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the more efficient dose for the treatment of
      rhinitis/rhinoconjunctivitis against grass pollen allergy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind placebo-controlled study. The subjects will receive medication during 4 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration required to elicit a positive response after nasal provocation test (NPT)</measure>
    <time_frame>4 months</time_frame>
    <description>Change in the threshold concentration of grass allergen extract, measured in Histamine Equivalent Prick per ml (HEP/ml), needed to trigger a positive response after nasal provocation test (NPT) assessed by acoustic rhinometry.
This will be compared between the beginning and end of the trial and among active groups and placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose finding skin prick test</measure>
    <time_frame>4 months</time_frame>
    <description>Comparison between the beginning and end of the trial and among active groups and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine production by T cells specific allergen</measure>
    <time_frame>4 months</time_frame>
    <description>Comparison between the beginning and end of the trial and among active groups and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin production by B cells specific allergen</measure>
    <time_frame>4 months</time_frame>
    <description>Comparison between the beginning and end of the trial and among active groups and placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotypic and functional analysis of dendritic cells</measure>
    <time_frame>4 months</time_frame>
    <description>Will be analyzed changes in the frequency of plasmacytoid dendritic cells, myeloid dendritic cell and Treg cells in peripheral blood, between the beginning and end of the trial and among active groups and placebo
The frequencies of peripheral blood mononuclear cells in each of the above populations is determined before and after treatment with mannosylated polymers by flow cytometry after staining with specific antibodies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by MG56-SIT-012</measure>
    <time_frame>4 months</time_frame>
    <description>Comparison between the beginning and end of the trial and among active groups and placebo</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Rhinitis</condition>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>MG56 Mannosylated 60 subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 MTU/ml of subcutaneous immunotherapy and sublingual placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG56 Mannosylated 100 subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 MTU/ml of subcutaneous immunotherapy and sublingual placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG56 Mannosylated 300 subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 MTU/ml of subcutaneous immunotherapy and sublingual placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG56 Mannosylated 500 subcutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 MTU/ml of subcutaneous immunotherapy and sublingual placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG56 Mannosylated 60 sublingual</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 MTU/ml of sublingual immunotherapy and subcutaneous placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG56 Mannosylated 100 sublingual</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 MTU/ml of sublingual immunotherapy and subcutaneous placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG56 Mannosylated 300 sublingual</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 MTU/ml of sublingual immunotherapy and subcutaneous placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MG56 Mannosylated 500 sublingual</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 MTU/ml of sublingual immunotherapy and subcutaneous placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sublingual Placebo subcutaneous</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sublingual and subcutaneous placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG56 Mannosylated 60 subcutaneous</intervention_name>
    <description>Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 60 MTU(Mannosylated Therapeutic Units)/ml subcutaneous</description>
    <arm_group_label>MG56 Mannosylated 60 subcutaneous</arm_group_label>
    <other_name>Manano</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG56 Mannosylated 100 subcutaneous</intervention_name>
    <description>Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 100 MTU(Mannosylated Therapeutic Units)/ml subcutaneous</description>
    <arm_group_label>MG56 Mannosylated 100 subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG56 Mannosylated 300 subcutaneous</intervention_name>
    <description>Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 300 MTU(Mannosylated Therapeutic Units)/ml subcutaneous</description>
    <arm_group_label>MG56 Mannosylated 300 subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG56 Mannosylated 500 subcutaneous</intervention_name>
    <description>Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 MTU(Mannosylated Therapeutic Units)/ml subcutaneous</description>
    <arm_group_label>MG56 Mannosylated 500 subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG56 Mannosylated 60 sublingual</intervention_name>
    <description>Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 60 MTU(Mannosylated Therapeutic Units)/ml sublingual</description>
    <arm_group_label>MG56 Mannosylated 60 sublingual</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG56 Mannosylated 100 sublingual</intervention_name>
    <description>Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 100 MTU(Mannosylated Therapeutic Units)/ml sublingual</description>
    <arm_group_label>MG56 Mannosylated 100 sublingual</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG56 Mannosylated 300 sublingual</intervention_name>
    <description>Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 300 MTU(Mannosylated Therapeutic Units)/ml sublingual</description>
    <arm_group_label>MG56 Mannosylated 300 sublingual</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MG56 Mannosylated 500 sublingual</intervention_name>
    <description>Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 MTU(Mannosylated Therapeutic Units)/ml sublingual</description>
    <arm_group_label>MG56 Mannosylated 500 sublingual</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Subcutaneous placebo</intervention_name>
    <description>Comparison between placebo and active group</description>
    <arm_group_label>MG56 Mannosylated 60 sublingual</arm_group_label>
    <arm_group_label>MG56 Mannosylated 100 sublingual</arm_group_label>
    <arm_group_label>MG56 Mannosylated 300 sublingual</arm_group_label>
    <arm_group_label>MG56 Mannosylated 500 sublingual</arm_group_label>
    <arm_group_label>Placebo Sublingual Placebo subcutaneous</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sublingual placebo</intervention_name>
    <description>Comparison between placebo and active group</description>
    <arm_group_label>MG56 Mannosylated 60 subcutaneous</arm_group_label>
    <arm_group_label>MG56 Mannosylated 100 subcutaneous</arm_group_label>
    <arm_group_label>MG56 Mannosylated 300 subcutaneous</arm_group_label>
    <arm_group_label>MG56 Mannosylated 500 subcutaneous</arm_group_label>
    <arm_group_label>Placebo Sublingual Placebo subcutaneous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Positive suggestive clinical history of intermittent or persistent moderate to severe
             rhinitis /rhinoconjunctivitis, with or without moderate asthma, due to grass pollen
             allergy

          -  Subjects with a positive skin prick-test (wheal sixe &gt;6 mm diameter) Specific
             immunoglobulin E (IgE, CAP &gt;3) to grass pollen

          -  Age between 14 and 65 years

          -  Both genders

          -  Subjects capable of giving informed consent

          -  Subjects capable of complying with the dosing regimen

          -  Subjects that have not received immunotherapy in the last 5 years

          -  Subjects presenting sensitization to another aeroallergens and or mites, cats or dogs,
             but that is considered clinically not relevant or no clinical interference with the
             nasal provocation test.

        Exclusion Criteria:

          -  Subjects outside of the age range.

          -  Subjects who have previously received immunotherapy for the treatment of the allergic
             rhinitis/rhinoconjunctivitis due to grass pollen and other allergens in the last 5
             years.

          -  Subjects that immunotherapy may be an absolute contraindication according to the
             criteria of the immunotherapy Committee of the Spanish society of Allergy and Clinical
             Immunology, and of the European Allergy and Clinical Immunology Immunotherapy
             Subcommittee may also include.

          -  Subjects with important symptoms of rhinoconjunctivitis /bronchial asthma in which the
             suspension of the systemic antihistamine treatment is contraindicated.

          -  Subjects with persistent severe or not controlled asthma , with a forced expiratory
             volume (FEV) &lt; 70 respect to the reference value in spite of the appropriate
             pharmacological treatment at the time of the inclusion in the trial.

          -  Subjects that have required oral corticosteroids in the 12 weeks previous to the
             inclusion in the trial.

          -  Subjects that have previously submitted a serious secondary reaction during the skin
             prick test

          -  Subjects in treatment with beta blockers.

          -  Unstable subjects from the clinical point of view (respiratory infection, febrile,
             acute urticaria, etc.) at the time of the inclusion in the clinical trial

          -  Subject with chronic urticaria in the last 2 years or hereditary angioedema.

          -  Subjects that have some pathology (hyperthyroidism, hypertension, heart disease, etc.)
             is contraindicated.

          -  Subjects with any other disease not associated with the rhinitis/rhinoconjunctivitis,
             but of potential severity and that could interfere with treatment and follow-up
             (epilepsy, psychomotor deterioration, diabetes, malformations, multi-operated, kidney
             diseases,...).

          -  Subjects with autoimmune disease (lupus, thyroiditis, etc.), tumor or with diagnosis
             of immunodeficiency diseases.

          -  Subject whose status prevents him from providing cooperation and or which present
             severe psychiatric disorders.

          -  Subject with known allergy to other components of the vaccine different from pollen of
             grasses.

          -  Subjects with lower airway diseases other than asthma such as emphysema or
             bronchiectasis.

          -  Direct investigator's relatives.

          -  Pregnant or women at risk of pregnancy and breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Subiza, PhD; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Subliza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Diéguez, PhD; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro Ojeda, PhD; MD</last_name>
    <role>Study Director</role>
    <affiliation>Clínica Ojeda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Ruiz Hornillos, PhD; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Infanta Elena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matilde Domínguez, PhD; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Puerta de Hierro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilio Solano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Ramón y Cajal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Moreno</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Atlas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pedro Guardia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen Macarena</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Agustín Orovigt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Viamed Santa Ángela de la Cruz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Caso</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Agustín</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alicia Alonso</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Alianza Médica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amparo Conde</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Nisa Sevilla Aljarafe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pedro Ojeda, PhD; MD</last_name>
    <phone>+34915623262</phone>
    <email>pedro.ojeda@clinicaojeda.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miguel Casanovas, PhD; MD</last_name>
    <phone>34916510010</phone>
    <email>mcasanovas@inmunotek.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clínica Atlas</name>
      <address>
        <city>Aranjuez</city>
        <state>Madrid</state>
        <zip>28300</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Moreno</last_name>
      <phone>+34918925373</phone>
      <email>doctorertony@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matilde Rodríguez, MD</last_name>
      <phone>911 916 000</phone>
      <email>matildesofia.rodriguez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Elena</name>
      <address>
        <city>Valdemoro</city>
        <state>Madrid</state>
        <zip>28342</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Ruiz Hornillos, MD</last_name>
      <email>jrhornillos@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nisa Aljarafe</name>
      <address>
        <city>Castilleja De La Cuesta</city>
        <state>Sevilla</state>
        <zip>41950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparo Conde</last_name>
      <phone>+34954464000</phone>
      <email>amparo_conde@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Agustín</name>
      <address>
        <city>Dos Hermanas</city>
        <state>Sevilla</state>
        <zip>41703</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Caso</last_name>
      <phone>+34 955050570</phone>
      <email>albertocasovazquez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLÍNICA Dr. SUBIZA</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Subiza, MD</last_name>
      <phone>915 615 594</phone>
      <email>jsubiza@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Ojeda</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Ojeda, MD</last_name>
      <phone>915 623 262</phone>
      <email>Pedro.ojeda@clinicaojeda.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Solano, MD</last_name>
      <phone>+34651421207</phone>
      <email>emilio.solano.solares@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOSPITAL UNIVERSITARIO 12 de OCTUBRE</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Diéguez, MD</last_name>
      <phone>917 772 426</phone>
      <email>mcarmen.dieguez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Guardia, Dr</last_name>
      <phone>+34955008000</phone>
      <email>pedro.guardia.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Viamed Santa Angola de la Cruz</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+954032000</phone>
      <email>agusoro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Alianza Médica</name>
      <address>
        <city>Valladolid</city>
        <zip>47001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Alonso</last_name>
      <phone>+34983338220</phone>
      <email>aliciaalonsogomez@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rhinitis / Rhinoconjunctivitis</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Grass pollen</keyword>
  <keyword>Allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

